Daily Anesthesiology Research Analysis
Analyzed 91 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology-adjacent trials stood out: a multicenter cluster RCT showed that automated cuff-pressure management with subglottic drainage reduced ventilator-associated pneumonia despite a negative primary endpoint on colonization; a patient- and assessor-blinded RCT demonstrated distinct immunologic and metastasis-related biomarker effects of common anesthetic adjuvants in colorectal cancer surgery; and a double-blind RCT found no meaningful difference between oxytocin bolus versus infusion for achieving early uterine tone after cesarean delivery.
Research Themes
- Automated airway device management to prevent ventilator-associated pneumonia
- Immunomodulatory effects of anesthetic adjuvants in cancer surgery
- Obstetric anesthesia pharmacology: oxytocin administration strategies
Selected Articles
1. Personalized automatic management of tracheal cuff pressure and subglottic secretions drainage to prevent pneumonia in critically ill intubated patients. The MICROINHALO multicenter randomized controlled trial.
In a multicenter cluster RCT, automated, personalized endotracheal cuff-pressure control with active subglottic secretion drainage did not reduce day-3 tracheal colonization versus manual care but significantly reduced both clinically diagnosed and microbiologically confirmed VAP. The intervention also maintained cuff pressures within the safety range more consistently and increased subglottic drainage volumes.
Impact: Despite a negative primary outcome, the trial demonstrates clinically meaningful VAP reduction with a scalable, device-driven strategy, addressing a persistent ICU complication.
Clinical Implications: Consider adopting automated cuff-pressure control with active subglottic drainage where available to reduce VAP, while recognizing the lack of effect on early colonization and the need for confirmatory trials to inform guidelines.
Key Findings
- Primary endpoint (day-3 tracheal colonization) showed no difference: 37% vs 41.5% (P=0.52).
- Clinically diagnosed VAP was significantly lower with automation: 12.6% vs 24.4% (P=0.016).
- Microbiologically confirmed VAP was also reduced: 10.2% vs 19.5% (P=0.039).
- Fewer cuff-pressure readings outside safety range and greater daily subglottic drainage with automation.
Methodological Strengths
- Cluster-randomized multicenter design with trial registration (NCT05403320).
- Objective device-derived exposure with standardized outcome definitions.
Limitations
- Open-label design and negative primary endpoint raise risk of type I error in secondary outcomes.
- Generalizability may depend on specific devices and ICU workflows.
Future Directions: A confirmatory, adequately powered trial with VAP as the primary endpoint and cost-effectiveness analyses is warranted; mechanistic substudies could clarify whether improved cuff-pressure stability mediates VAP reduction.
PURPOSE: The MICROINHALO trial investigated whether personalized management of endotracheal tube cuff pressure (Pcuff) based on exhaled CO METHODS: This cluster-randomized, international, open-label trial (NCT05403320) enrolled adult patients at 10 ICUs. They were randomly assigned to receive either an endotracheal tube equipped with automatic Pcuff management and SSD, or a conventional one with manual Pcuff management and manual SSD. The primary endpoint of the study was the rate of bacterial tracheal colonization (> 10 RESULTS: Among 270 randomized patients, 250 were included in the analysis: 127 allocated to the automatic management group and 123 to the manual management group. Bacterial tracheal colonization on day 3 occurred in 47 (37%) patients in the automatic management group and in 51 (41.5%) patients among controls (absolute difference - 4% [95% CI - 16 to 8], P = 0.52). The rate of clinically diagnosed (12.6% vs. 24.4%, P = 0.016) and microbiologically confirmed ventilator-associated pneumonia (VAP) (10.2% vs. 19.5%, P = 0.039) was significantly lower in the automatic management group, along with a lower percentage of Pcuff values outside the safety range (10.2% vs. 24.4%, P < 0.001) and a higher daily SSD volume (25 [8-41] mL vs. 10.5 [6-17] mL, P < 0.001). CONCLUSIONS: Among critically ill intubated patients, personalized automatic management of tracheal cuff pressure and subglottic secretion drainage was not superior to manual management to prevent tracheal colonization. Further research is warranted to confirm the observed effect on VAP rate reduction.
2. Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial.
In a patient- and assessor-blinded RCT of colorectal cancer surgery, lidocaine increased early postoperative MMP-9 compared to dexmedetomidine and intrathecal morphine, while dexmedetomidine shifted CD8+ T cells toward a CD73+ phenotype and reduced CD39−CD73− subsets. Intrathecal morphine provided superior dynamic analgesia with minimal apparent immune perturbation.
Impact: This trial advances mechanistic understanding of how common anesthetic adjuvants modulate metastasis-related biology and T-cell phenotypes, informing the design of onco-anesthesia strategies.
Clinical Implications: While not practice-changing yet, selection of adjuvants may warrant consideration of potential pro-metastatic signaling (e.g., lidocaine-associated MMP-9 rise) versus immunophenotypic shifts (dexmedetomidine) and analgesic benefits (intrathecal morphine), pending long-term oncologic outcome data.
Key Findings
- Group×time interaction for MMP-9 was significant; at 1 hour, MMP-9 was higher with lidocaine vs dexmedetomidine (log-scale difference 0.333; P=0.009) and vs intrathecal morphine (0.424; P=0.033).
- Dexmedetomidine increased CD73+CD8+ T cells (vs lidocaine; P=0.050) and reduced CD39−CD73−CD8+ T cells (vs ITM P=0.018; vs lidocaine P=0.029).
- Intrathecal morphine achieved lower dynamic pain scores than the other groups; adverse events were mild and similar across groups.
Methodological Strengths
- Randomized, patient- and assessor-blinded three-arm design.
- Prespecified biomarker endpoints with immune phenotyping at multiple time points.
Limitations
- Modest sample size and short follow-up limited to early perioperative windows.
- Surrogate biomarker outcomes without long-term oncologic endpoints; multiple comparisons raise false-positive risk.
Future Directions: Prospective trials powered for cancer recurrence and survival are needed to test whether perioperative adjuvant choices alter long-term oncologic outcomes; mechanistic studies should link T-cell phenotype changes to functional anti-tumor immunity.
BACKGROUND: Anesthetic adjuvants used in multimodal analgesia-including intravenous lidocaine, dexmedetomidine, or intrathecal morphine (ITM)-may differentially affect immune responses and metastasis-related pathways in colorectal cancer surgery. Their comparative effects on these pathways remain poorly understood. METHODS: In this prospective, randomized, patient- and assessor-blinded trial, adults undergoing elective laparoscopic or robotic colorectal cancer resection were allocated to receive intravenous lidocaine, dexmedetomidine, or ITM. The primary outcome was plasma matrix metalloproteinase-9 (MMP-9) concentration at 1 hour postoperatively. Secondary outcomes included other metastasis-promoting biomarkers (MMP-2, VEGF, IL-6), immune cell subsets (T and NK cells), and CD39/CD73 expression on T lymphocytes at 1 hour postoperatively and postoperative day 1. Clinical outcomes-including pain scores, opioid consumption, and complications-were also assessed. RESULTS: Of the 114 enrolled patients, 109 completed the study and were analyzed (ITM group = 37, DEX group = 34, LIDO group = 38). Overall group × time interaction was significant for MMP-9 (P = .028). At 1 hour, MMP-9 was higher in LIDO group than in the DEX group (difference on the log scale, 0.333; 95% confidence interval [CI], 0.0642-0.601; P = .009) and in the ITM group (0.424; 95% CI, 0.0248-0.823; P = .033). The DEX group was associated with increased CD73+CD8+ T cells compared with the LIDO group (difference on the logit scale: 0.669; 95% CI, 0.000987-1.34; P = .050), and with decreased CD39-CD73-CD8+ T cells compared with the ITM group (-0.695; 95% CI, -1.3 to -0.0908, P = .018) and the LIDO group (-0.645; 95% CI, -1.24 to -0.05, P = .029). The ITM group was associated with lower dynamic pain scores than the other groups. Rescue antiemetic use was less frequent with the DEX group, whereas other adverse events were mild and comparable across groups. CONCLUSIONS: Anesthetic adjuvants exerted differential effects on perioperative biomarkers and immune profiles relevant to tumor progression. Compared with the other groups, lidocaine was associated with higher MMP-9 levels, dexmedetomidine with relative shifts toward an immunosuppressive T-cell phenotype, and intrathecal morphine with superior analgesia with minimal immune impact. Further studies are warranted to determine whether multimodal analgesia strategies influence long-term oncologic outcomes.
3. Randomized Double-Blinded Clinical Trial of Oxytocin Bolus versus Infusion in Elective Cesarean (INBOX Trial).
This double-blind RCT found no difference between oxytocin bolus and infusion in achieving adequate uterine tone at 2 minutes after cord clamping during elective cesarean delivery. Although median blood loss was slightly lower with bolus, the effect size was small and unlikely to be clinically meaningful; safety profiles were comparable.
Impact: Provides high-quality, blinded RCT evidence clarifying that administration mode does not materially affect early uterine tone, supporting flexibility in oxytocin delivery.
Clinical Implications: Either bolus or infusion can be used after cord clamping in elective cesarean under spinal anesthesia, with selection guided by workflow and clinician preference; any blood loss difference with bolus is likely not clinically important.
Key Findings
- Adequate uterine tone at 2 min: 83.3% (bolus) vs 78.2% (infusion); P=0.483.
- Median blood loss slightly lower with bolus (558 mL) vs infusion (687 mL), P=0.0438; Hodges-Lehmann estimate 82 mL (95% CI 2–168).
- Safety endpoints (hypotension, phenylephrine use, nausea, additional uterotonics) and patient satisfaction were similar.
Methodological Strengths
- Randomized, double-blind design with pharmacy-prepared masked study drugs.
- Comprehensive safety assessment and standardized outcome measures.
Limitations
- Single-center with modest sample size, potentially underpowered for rare outcomes.
- Findings may not generalize to emergent cesarean or different anesthesia techniques.
Future Directions: Larger multicenter trials could examine hemodynamic profiles and cumulative uterotonic requirements across diverse populations, and assess outcomes such as postpartum hemorrhage requiring intervention.
BACKGROUND: Oxytocin is the most widely used uterotonic for postpartum hemorrhage prevention, yet high-quality data comparing bolus versus infusion administration are limited. Given the very high uterine blood flow at term, rapid achievement of uterine tone is critical to minimize blood loss. We hypothesized that bolus administration leads to a greater likelihood of attaining adequate uterine tone at 2 minutes. METHODS: In this randomized, double-blinded clinical trial, 121 patients undergoing elective cesarean delivery under spinal anesthesia were randomized 1:1 to receive oxytocin by bolus or infusion after cord clamping. Masked study drugs were prepared by the investigational pharmacy to maintain blinding of the anesthesiologist, obstetrician, and study personnel. The primary end point was adequate uterine tone at 2 minutes. Secondary end points included patient satisfaction, time to adequate uterine tone, quantitative blood loss, postpartum hemorrhage (blood loss greater than 1000 mL), and safety measures (heart rate, blood pressure, phenylephrine dose, chest pain, nausea/vomiting, additional uterotonic use, and intensive care unit admission). RESULTS: Of 121 patients enrolled, 115 were analyzable (6 screen failures received no study drug); 114/115 received oxytocin per protocol. Baseline characteristics were similar between groups. Adequate uterine tone at 2 minutes (primary end point) was similar in bolus (50/60, 83.3%) vs infusion (43/55, 78.2%), P = .483. Patient satisfaction scores were also not significantly different (P = .495) between the two arms, with both the bolus and infusion arms having medians and interquartile range (IQRs) of (10 [IQR 10-10]). Median blood loss was slightly lower with bolus (558 mL [IQR 429-733]) vs infusion (687 mL [IQR 480-826], P = .0438; Hodges-Lehmann estimate of 82 mL [95% confidence interval {CI}, 2-168 mL]). Phenylephrine dosage and rates of postpartum hemorrhage, nausea, and additional uterotonic use were similar between groups (all P > .28). Rates of postpartum hemorrhage, hypotension, phenylephrine use, nausea, and additional uterotonic use were similar. CONCLUSIONS: There was no statistically significant difference in the frequency of achieving adequate uterine tone at 2 minutes between oxytocin given by infusion or bolus. Although the bolus group demonstrated statistically lower blood loss, the magnitude of this difference was small (upper confidence limit of 168 mL) and is unlikely to be clinically significant. Both methods showed comparable safety profiles.